Company intelligence / Profile preview

Arbor Pharmaceuticals, LLC

Atlanta, Georgia, United Statesorpha.net ↗

Ownership: Private
Employees: ~86
Development stage: Commercial

Overview

Arbor Pharmaceuticals markets FDA-approved prescription products across multiple therapeutic areas. They are actively involved in the treatment of Glioblastoma Multiforme through their product Gliadel Wafer, a carmustine implant used as an adjunct to surgery and radiation for both newly-diagnosed and recurrent cases[3].

Therapeutic areas: CardiovascularEndocrinologyOtherOncologyNeurologyInfectious Diseases
Modalities: Small molecules (prescription drugs)
Industry: Biotech

Drug pipeline

5 assets

centanafadine

Phase 3

Indications: Attention-deficit/hyperactivity disorder (ADHD)

4 more assets in the full pipeline.

Request access →

Partnerships

Kaken Pharmaceutical (licensed Sklice)[6]

Beyond the preview

Go deeper on Arbor Pharmaceuticals, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arbor Pharmaceuticals, LLC.

Explore the full profile